Germany - Drugs

Description

The participating health insurance funds are pursuing the goal of concluding rebate contracts with all suitable pharmaceutical companies in accordance with Section 130a (8) SGB V for the active ingredient Etravirin. The contract is concluded within the framework of the health insurance funds' open-house original procedure:Individual negotiations on contract content are not conducted; uniform conditions apply. The health insurers do not guarantee exclusivity to individual contract partners. The contract period is a maximum of 24 months starting on 01.04.2022. The contract ends on 31.03.2024 at the latest, irrespective of the date on which the contract was concluded. All further information can be found in the participation and contract documents. In the event of patent expiry before 31.03.2024, the contract will automatically end at the end of the month of patent expiry.
It is possible to join this open house original procedure at any time during the term of the contract. Due to the existence of industrial property rights with regard to the active ingredient covered by the agreement, the participation and contract documents will only be made available to those pharmaceutical companies that offer/market medicinal products for the active ingredient covered by the agreement or credibly demonstrate to TK that they intend to offer/market medicinal products for the active ingredient covered by the agreement within the term of the agreement.A contract will be concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration of approval and company) and confirm this in electronic form in accordance with Section 126a of the German Civil Code (BGB).This announcement does not relate to the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The designation of the procedure "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. Neither this nor the use of the "TED" medium is in any way connected with submission to procurement law regulations, the application of which is not mandatory by law or procurement regulations.

Opportunity closing date

31 March 2024

Value of contract

to be confirmed